Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysisAndrea Casadei‐Gardini, Alessandro Cucchetti, Mario Scartozzi et al.|Liver International|2021Cited by 60
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Shin Maeda, Hisashi Hidaka et al.|Hepatology Research|2020Cited by 38
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Margherita Rimini, Toshifumi Tada et al.|Liver International|2021Cited by 25